Eliza Slawther
Senior Writer, Europe
Eliza Slawther began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care.
Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.
Latest From Eliza Slawther
EU Proposal To Have Guidance Transition Periods “Does Not Make Sense”
A proposed position paper on time periods for notified bodies to roll out guidance documents aims to introduce greater predictability. But has the EU notified body organization gone too far with its proposals?
Industry View: EU Plans To Extend Product Liability Rules Bad News For Medtech
A proposed revision to the European Commission’s Product Liability Directive that will extend user compensation eligibility to products such as medical smartphone apps could “needlessly disrupt” innovation in the EU, trade group MedTech Europe warns.
Industry Welcomes Changes To EU AI Act, But Fears Of Overlap Remain
While recently proposed amendments to the draft EU legislation on Artificial Intelligence are a step in the right direction for medical devices, trade associations MedTech Europe and COCIR warn that the potential for regulatory conflicts remains.
EU Position Paper Outlines Notified Body View On Hybrid MDR/IVDR Audits
Hybrid audits of quality management systems (QMS) can satisfy certain requirements of new EU medtech regulations while improving efficiencies, TEAM-NB has said. In a new position paper, the association details how and when hybrid audits are appropriate.
UK’s Early Value Assessment Pilot Is ‘Catalyst’ For Wider Change - NICE
NICE’s early value assessment (EVA) pilot for medtech will have failed unless it changes the way that medical devices “as a whole” are evaluated in the UK, according to Mark Chapman, the organization’s interim director of medical technology.
MedTech Europe’s 2022 Report: Germany Top For Medical Device And IVD Sales
MedTech Europe’s latest annual report unveils facts and figures that contextualize the European market against the global stage and highlight which countries are leading the way for medtech sales and employment.